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  bjective: This study investigated whether some components of the extracellular matrix and CD68 expression may drive the
differences between the central giant cell granuloma (CGCG) of the jaws and giant cell tumor (GCT) of long bones, which
present distinct evolution and clinical behavior. Material and Methods: Eight cases of CGCG and 7 cases of GCT were selected
and immunohistochemically analyzed to verify the pattern of expression of CD68, tenascin (Tn) and fibronectin (Fn). Results:
A large number of the mononuclear cells and multinucleated giant cells CD68+ was observed in both of the studied lesions,
indicating histiocyte/ macrophage origin. Seven cases of CGCG of the jaws showed intense staining of Fn, with uniform
distribution predominantly. In all 7 cases of GCT of long bones the Fn displayed intense expression, with distribution pattern
varying from uniform to reticulate/fibrillar. Six cases of CGCG were intensively stained by Tn, presenting focal expression in
half of specimens, and reticulate/ fibrillar pattern of expression in 4 cases. All cases of GCT of the long bones presented intense
expression of Tn, uniform distribution, and reticulate/fibrillar pattern of expression in four cases. Conclusions: The
immunoexpression of CD68 in mononuclear cells and multinucleated giant cells and staining patterns of Fn and Tn were similar
in both entities. These findings indicate that these proteins could not be used to explain the differences between the CGCG of
the jaws and GCT of the long bones.
Uniterms: Giant cell granuloma; Giant cell tumor; Fibronectins; Tenascin; CD68.
INTRODUCTION
Central giant cell granuloma of the jaws and giant cell
tumor of long bones are well-recognized entities revealing
benign nature16. Their clinical behavior8,13,29, prognostic
factors and the histogenesis have been subject of several
studies. In spite of that, these questions remain
unclear11,16,23,26.
Morphologic studies performed in order to compare
CGCG and GCT features have shown that although most of
jaw lesions may be distinguished from tumor of long bones
on histological appearance, many jaw lesions display the
histological profile of the tumor of long bones. Whitaker
and Waldron29 (1993) reported that CGCG of the jaws and
GCT of long bones could represent the development of a
single pathologic process that may be influenced by patient’s
age, location and other unknown factors. The true GCT of
the jaws is rare and local prognosis is considered worse in
GCT than in CGCG8.
The biologic behavior of CGCG of the jaws ranges from
a quiescent lesion with absence of symptoms, root
resorption or cortical perforation, slow growth, and low
recurrence rate, to an aggressive pathological process,
characterized by pain, rapid growth, root resorption, cortical
perforation, and a high recurrence rate8,21. The GCT of long
bones is a rare benign neoplasm, characterized by local
aggressiveness, high recurrence rates and metastasis to the
lung14,16,21,25. The principal characteristic of GCT is the
unpredictable biological behavior28.
An immunohistochemical study to determine the
immunoprofile of the mononuclear cells and proliferative
compartment of CGCG of the jaws in clinically aggressive
and non-aggressive lesions, using antibodies to CD34,
CD68, factor XIIIa, alfa-smooth muscle actin, prolyl 4-
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hydroxylase, Ki-67, and p53 protein, revealed that these
lesions are primarily fibroblastic (and myofibroblastic) with
macrophages playing a secondary role, and that it is not
possible to predict the behavior of the CGCG of the jaws
from histologic features, immunophenotypic or proliferation
parameters19. Other studies have demonstrated
immunoreactivity of mononuclear cells and multinucleated
cells to CD68 in giant cell lesions, suggesting a histiocyte/
macrophage origin for a subset of cells of these
lesions6,16,19,28. CD68 is a transmembrane glycoprotein of
unknown function, being strongly expressed by human
monocytes and tissue macrophages10,20.
Several groups of investigators have carried out
immunohistochemical studies to observe the
immunoreactivity, and distribution pattern of the fibronectin
and tenascin in dermatologic diseases22, giant cell
granulomas5, odontogenic cysts18, and normal oral mucosa,
epithelial dysplasia and fibroepithelial hyperplasia3.
Fibronectin has several functions, being one of the main
cell-matrix ligands2. It is found prominently in the matrix of
many connective tissues and is more abundant during
embryonic development, tissue remodeling4 and within a
wide variety of basement membranes1. The fibronectin
arrangement in focal adhesions stimulates the cellular growth
by increasing the cell entry into the S-phase of cell cycle9.
The proliferative activity and newly formed vessels
associated to a fibronectin variant support the idea that
some types of fibronectin could be important prognosis
factors12.
Tenascin is expressed in epithelial-mesenchymal
interactions during embryogenesis and tumorigenesis. This
protein has demonstrated significant variation in the
distribution and immunoreactivity intensity within individual
samples of several lesions17 and pathologic processes7, being
strongly expressed in epithelial malignant tumors24.
The purpose of this study was to investigate the CD68
expression in mononuclear and multinucleated giant cells
and the pattern of immunoreactivity and distribution of
fibronectin and tenascin between CGCG of the jaws and
GCT of long bones, in order to analyze if there are differences
in the expression of these proteins that could be used to
distinguish the studied lesions.
MATERIAL AND METHODS
Eight cases of CGCG of the jaws were retrieved from the
files of the Oral Pathology Discipline of the Federal
University of Rio Grande do Norte, School of Dentistry, and
7 cases of GCT of long bones were obtained from the files of
the Pathology and Cytology Laboratory of Aracaju - SE.
Microscopic slides on each case were reviewed and
histologic features of multinucleated giant cells, mononuclear
cells and stroma were assessed.
For the immunohistochemical study, 3-µm sections were
obtained from the formalin-fixed paraffin-embedded surgical
specimens of the lesions. Immunohistochemical staining
was carried out using the streptavidin-biotin-peroxidase
complex (SABC) method. The following antigens were
evaluated: CD68 (macrophage-associated monoclonal
antibody, KP-1(2) clone, 1:50; Dako, Glostrup, Denmark),
incubated at 4°C overnight; fibronectin (A-245 clone,1:600;
Dako), incubated at room temperature for 120 min and
tenascin (TN2 clone, 1:50; Dako), incubated at 4°C overnight.
For the antibodies against fibronectin and tenascin the
tissue sections were previously treated with 0.1% and 0.4%
pepsin respectively, and for the CD68 the antigen retrieval
was processed in citric acid in three cycles for 5 minutes
(700watts). Diaminobenzidine was used as chromogen.
The immunoreactivity expressed by CD68, fibronectin
and tenascin antigen was evaluated in all the cases by light
microscopy, using the following parameters: positive (+)
and negative (-) staining of the mononuclear cells and
multinucleated giant cells for the CD68 antigen, and degrees
of staining intensity (intense or weak), distribution (uniform
scattered or in focal areas) and expression pattern (fibrillar,
reticular and fibrillar/reticular) of the fibronectin and tenascin
in the interstitial extracellular matrix and around blood
vessels. Two previously calibrated examiners carried out
the immunohistochemical evaluation of the specimens.
RESULTS
CD68
CD68 positive cells were detected in many mononuclear
cells and in the majority of multinucleated giant cells of the
CGCG of the jaws (Figure 1) and GCT of long bones (Figure
2) evaluated.
Fibronectin and Tenascin
The immunostaining results for fibronectin and tenascin
in CGCG and GCT are summarized in Tables 1-4, and depicted
in Figures 3-6.
DISCUSSION
Although the origin of the cells present in giant cell
lesions has been investigated through histochemistry23,
ultrastructural19,23 and immunohistochemical methods13,23,
the pathogenesis and nature of these lesions are still unclear.
Whether the CGCG of the jaws and the GCT of long
bones are really a single pathologic process is also an
unanswered question. As stated by Whitaker and Waldron29
(1993), CGCG of the jaws and GCT of long bones could
represent the development of a single pathologic process,
modified by age of the patient, location, and other unknown
factors.
In attempt to clarify whether CGCG and GCT are separate
entities or variants of the same disease, Souza, et al.21 (1999)
performed an immunohistochemical study of the cell cycle
related proteins p53, MDM2, Ki-67 and PCNA in samples of
both lesions. These authors verified wide expression of
MDM2 in CGCG and in GCT and no immunoreactivity to
p53 in both lesions. Comparing the proliferative activity
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between lesions, GCT revealed a reduced percentage of Ki-
67- and PCNA-positive cells. In view of their results, these
authors suggest that p53 inactivation by MDM2 expression
may be involved in the pathogenesis of CGCG and GCT.
In addition, Souza, et al.21 (1999) state that the differences
observed in proliferative activity do not explain the different
biological behavior of CGCG and GCT, as reactive lesions
may show increased proliferative activity. The authors
FIGURE 1 - Multinucleated giant cells and individual
mononuclear cells CD68 positive in central giant cell
granuloma of the jaws (arrow) (SABC – 200x)
FIGURE 2 - Multinucleated giant cells and individual
mononuclear cells CD68 positive in giant cell tumor of
long bones (arrow) (SABC – 400x)
FIGURE 3 - Fibronectin immunoreactivity in central giant
cell granuloma of the jaws. Fibrillar organization pattern
following the collagen fibers (SABC – 200x)
FIGURE 4 - Fibronectin immunoreactivity in giant cell tumor
of long bones. Reticulate/fibrillar organization pattern and
positive staining around the basement membrane of blood
vessels (arrow) (SABC – 100x)
FIGURE 5 - Tenascin immunoreactivity expression in central
giant cell granuloma of the jaws. Reticulate/fibrillar
organization pattern (SABC – 100x)
FIGURE 6 - Tenascin immunoreactivity in giant cell tumor of
long bones. Reticulate organization pattern and positive
staining around the basement membrane of blood vessels
(arrow) (SABC – 200x)
312
ARAGÃO M do S, PIVA M R, NONAKA C F W, FREITAS R de A, SOUZA L B de, PINTO L P
emphasize that since CGCG and GCT occur in different sites,
it is difficult to compare accurately their biological evolution.
Nevertheless, Souza, et al.21 (1999) suggest that CGCG and
GCT could represent variants of the same disease.
CD68 monocyte-macrophage lineage marker has been
often used in the investigation of giant cells. Our results
demonstrated positive reactivity of many mononuclear cells
and most of multinucleated giant cells to CD68 in both
lesions studied, suggesting the existence of a histiocyte/
macrophage origin for some of the cellular components of
CGCG and GCT, as shown by Carvalho, et al.6 (1995), Masui,
et al.16 (1998), O’Malley, et al.19(1997) and Werner28 (2006).
In addition, Werner28 (2006) and Wülling, et al.30 (2001)
emphasize that mononucleated histiocytic cells and
multinucleated giant cells expressing CD68 antigen are
recruited secondarily and do not constitute the actual
neoplastic cell population in GCT. According to these
authors, the proliferatively active neoplastic tumor cells,
also described as GCT stromal cells, constitute varying
portions of the tumoral tissue and do not belong to
monocytic-histiocytic system.
Itonaga, et al.11 (2003), in a study performed on CGCG,
identified the presence of cell subsets similar to those
reported in GCT. These authors verified that mononuclear
cells were constituted by two cell subsets, one revealing a
macrophagic/ osteoclastic-precursor immunoprofile and
another subset constituted by mesenchymal cells showing
a immunoprofile towards a fibroblast/osteoblast lineage,
expressing prolyl-4-hydroxylase and vimentin, being
negative for macrophage associated antigens (CD11a,
CD11b), leucocyte common antigen (LCA) and CD68. In
addition, the conspicuous expression of proliferating cell
nuclear antigen (PCNA) in the latter cell subset led Itonaga,
et al.11 (2003) to suggest that the proliferative component of
CGCG would be represented by a mesenchymal stromal cell
which had the capacity to differentiate along fibroblast/
Case Expression     Distribution Staining
 intensity Pattern
1 ++ uniform Reticulate
2 ++ uniform Fibrillar
3 + uniform Fibrillar
4 ++ uniform reticulate/ fibrillar
5 ++ uniform reticulate/ fibrillar
6 ++ uniform reticulate/ fibrillar
7 ++ uniform reticulate/ fibrillar
8 ++ Uniform Fibrillar
TABLE 1- Fibronectin expression intensity, distribution and
staining pattern in interstitial extracellular matrix of the
central giant cell granulomas of the jaws
Source: Postgraduate Program in Oral Pathology of UFRN.
++ = intense immunoreactivity; + = weak immunoreactivity;
- = negative immunoreactivity.
Case Expression     Distribution Staining
 intensity Pattern
1 ++ uniform reticulate/ fibrillar
2 ++ uniform reticulate/ fibrillar
3 ++ uniform reticulate/fibrillar
4 + focal fibrillar
5 + uniform reticulate/fibrillar
6 + focal reticulate
7 ++ uniform reticulate/fibrillar
TABLE 2- Fibronectin expression intensity, distribution and
staining pattern in interstitial extracellular matrix of the giant
cell tumors of long bones
Source:  Pathology and Cytology Laboratory, Aracaju, SE,
Brazil. ++ = intense immunoreactivity; + = weak
immunoreactivity; - = negative immunoreactivity.
Case Expression     Distribution Staining
 intensity Pattern
1 ++ focal reticulate
2 ++ focal reticulate
3 ++  uniform reticulate
4 ++ uniform reticulate/ fibrillar
5 + focal fibrillar
6 ++  uniform reticulate/ fibrillar
7 ++ focal reticulate/ fibrillar
8 ++ uniform reticulate/ fibrillar
TABLE 3- Tenascin expression intensity, distribution and
staining pattern in interstitial extracellular matrix of the
central giant cell granulomas of the jaws
Source: Post graduation Program in Oral Pathology of
UFRN. ++ = intense immunoreactivity; + = weak
immunoreactivity; - = negative immunoreactivity.
Case Expression     Distribution Staining
 intensity Pattern
1 ++ uniform reticulate
2 ++ uniform reticulate/ fibrillar
3 ++ uniform reticulate/ fibrillar
4 ++ uniform reticulate/ fibrillar
5 ++ uniform reticulate
6 ++ uniform reticulate
7 ++ uniform reticulate/ fibrillar
TABLE 4- Tenascin expression intensity, distribution and
staining pattern in interstitial extracellular matrix of the giant
cell tumors of long bones
Source:  Pathology and Cytology Laboratory, Aracaju, SE,
Brazil. ++ = intense immunoreactivity; + = weak
immunoreactivity; - = negative immunoreactivity.
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osteoblast lines.
Accordingly, Liu, et al.15 (2003) verified the expression
of vacuolar H+-ATPase (V-ATPase), carbonic anhydrase II
(CA II), cathepsin K, MMP-9 and tartarate-resistant acid
phosphatase (TRAP) in multinucleated giant cell of CGCG,
thus confirming the characteristics of an osteoclastic
phenotype. Moreover, the authors observed strong
expression of receptor activator of NF-kB ligand (RANKL),
an important cytokine necessary and sufficient for
osteoclastogenesis, by the spindle stromal cells and the
expression of receptor activator of NF-kB (RANK) by round
mononuclear and multinucleated giant cells. Therefore, Liu,
et al.15 (2003) summarizes that stromal spindle cells of CGCG
induce the bone-resorption function by secreting RANKL
which interacts with its receptor in multinucleated giant cells,
similar to the normal situation of mature osteoclasts.
The study performed by Wang, et al.27 (2006) described
strong similarities of the osteoclastogenesis process in
lesions containing multinucleated giant cells. These authors,
analyzing the mRNA and protein levels of c-Src, a molecule
involved in an important signaling pathway downstream of
RANK, verified the expression of this component both in
CGCG of the jaws and GCT of long bones with no significant
differences. These results led Wang, et al.27 (2006) to suggest
that c-Src may be a common signaling cascade during
osteoclastogenesis in CGCG and GCT, regardless the location
either in the jaws or long bones.
Only few studies analyzing the constitution of the
extracellular matrix of CGCG and GCT have been performed.
Within this subject, Ueda, et al.25 (1996), studying
components of vascular basement membranes and matrix
metalloproteinases in GCT of long bones, reported important
findings. These authors verified weak or absence of
expression of collagen IV and laminin in vascular basement
membranes close to multinucleated giant cells revealing
strong expression of MMP-9. In addition, Ueda, et al.25 (1996)
described a reduction of MMP-9 level in multinucleated giant
cells present within vessels, suggesting that MMP-9 may
be consumed during migration of tumor cells through the
blood vessel basement membrane. Therefore, these authors
implied that MMP-9 is an important protease for vascular
invasion of multinucleated giant cells in GCT.
Kumta, et al.14 (2003), analyzing the expression of
vascular endothelial growth factor (VEGF) and MMP-9 in
many osseous lesions, correlating to radiographic staging
of osteolytic destruction, observed that lesions in advanced
stages and recurrent lesions, including the GCT, revealed
higher expression of MMP-9 and VEGF. According to Kumta,
et al.14 (2003) the level of MMP-9 and VEGF expression may
provide some prognostic indication of biologically
aggressive behavior and local disease recurrence in
osteolytic lesion affecting bone.
Interesting findings in relation to VEGF expression have
also been observed in CGCG. Vered, et al.26 (2006) studied 41
cases of CGCG for the immunoreactivity to VEGF and basic
fibroblastic growth factor (bFGF) in relation to angiogenic
activity, assessed by a stereological method for measuring
microvascular volume. Despite the high levels of
immunoreactivity to VEGF and bFGF in the lesions, found
prominently in mononuclear stromal cells and multinucleated
giant cells, it was observed a low mean microvascular volume.
Therefore, Vered, et al.26 (2006) state that VEGF and bFGF
expression could be related to stimulation of
osteoclastogenesis in CGCG, suggesting that high levels of
VEGF- and bFGF-producing cells in a CGCG would be related
to a more aggressive biological behavior.
Fibronectin is a glycoprotein of the extracellular matrix
and plasma protein that has function in cell adhesion and
spreading. It is found in most body fluids, connective
tissues, granulation tissues and basement membranes1,4.
This protein plays several biological functions and an
important role in neoplastic development and other
pathological processes, including those that occur in oral
cavity1,2,3,5.
Fibronectins may be associated with invasion and
metastasis. Therefore, fibronectin variants could be used
as possible prognostic factor12. Our study showed that
fibronectin immunoreactivity was readily detectable in both
giant cell lesions. Staining was exclusively stromal, with no
evidence of an intracellular positive reaction. The variable
staining intensity observed between CGCG of the jaws and
GCT of long bones was not significant to be used as
diagnostic differential factor.
In the present study, fibronectin reticulate/fibrillar was
the most common pattern of organization in the evaluated
lesions, followed by single fibrillar and reticulate organized
patterns. We have hypothesized that the fibronectin different
organization patterns seem non-significant, as the
prominence of the mixed pattern revealed that fibronectin
can be presented under the reticulate and fibrillar aspects in
a single case.
Although fibronectin reticular organized pattern had been
associated with the presence of inflammatory cells18,22, our
findings do not confirm this fact because this pattern type
could be detected in some lesions that did not present
inflammatory process. The fibrillar organized pattern of
fibronectin staining, following the collagen fibers, in CGCG
of the jaws, described in this study is consistent with
previous study carried out by Cardoso5 (2000).
Tenascin is a glycoprotein of the extracellular matrix
expressed in epithelial-mesenchymal interactions during
embryogenesis and tumorigenesis of several tissues7 that
plays an important role as a molecular mediator in
proliferation and progression in neoplastic processes24.
In this study, we observed intense immunoreactivity of
tenascin within individual specimens of GCT of long bones
and CGCG of the jaws and marked variation in its spatial
distribution, presenting focal organization in 4 cases of CGCG
of the jaws, whereas uniform distribution was detected in all
cases of GCT of the long bones.
The loose connective tissue between the fascicles
presenting inflammatory infiltrate has been associated with
increased tenascin expression24. Like Cardoso5 (2000) and
Mighell, et al.17 (1996), we also observed no association
between areas where inflammatory cells were present and
tenascin immunoreactivity enhancement.
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The findings of this study showed predominant
reticulate organized pattern of the tenascin in most of the
specimens of both of the analyzed lesions. In some cases, it
was observed as a single reticular pattern, but there were
cases revealing association with the fibrillar pattern. The
fibrillar pattern isolated was identified following the collagen
fibers, similar to that reported by Cardoso5 (2000) and
Tarquínio22 (1999). In this study, tenascin immunoreactivity
revealed similarities between both giant cell lesions studied.
CONCLUSIONS
Despite the low number of tissue specimens of CGCG
and GCT evaluated, that was a methodological limitation,
the findings of the present study revealed
immunohistochemical similarities between CGCG of the jaws
and GCT of long bones, supporting the observation that
sometimes these lesions are indistinguishable. Further
research is needed to clarify the pathogenesis and nature of
these giant cell lesions and other markers have to be
investigated in order to answer the question of whether
these lesions represent the development of a single
pathologic process or not.
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